OMERS Administration Corp’s BioMarin Pharmaceuticals BMRN Stock Holding History

OMERS Administration Corp’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,767	Closed	-$382K	–	945
2026 Q1	$382K	Hold	6,767	–	–	﹤0.01%	809
2025 Q4	$402K	Sell	6,767 -30,800	-82%	-$1.68M	﹤0.01%	739
2025 Q3	$2.03M	Hold	37,567	–	–	0.01%	407
2025 Q2	$2.07M	Buy	37,567 +7,500	+25%	+$442K	0.02%	370
2025 Q1	$2.13M	Buy	30,067 +22,172	+281%	+$1.49M	0.02%	366
2024 Q4	$519K	Buy	7,895 +1,340	+20%	+$89.8K	﹤0.01%	694
2024 Q3	$461K	Hold	6,555	–	–	﹤0.01%	680
2024 Q2	$540K	Buy	+6,555	New	+$546K	0.01%	657

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

OMERS Administration Corp's BMRN Position: Q2 2026 in Review

OMERS Administration Corp sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 6,767 shares — an estimated $382K sold.

OMERS Administration Corp first reported a position in BMRN in Q2 2024 and held it in 8 quarters. The position peaked at $2.13M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

OMERS Administration Corp reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
OMERS Administration Corp sold 6,767 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $382K.
OMERS Administration Corp first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 8 quarters.
OMERS Administration Corp's BioMarin Pharmaceuticals position peaked at $2.13M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.